In relation to the sp - have a look at Morgan's analyst coverage from September:
"We have updated our model to reflect the recent capital raising and set our valuation and price target at A$0.08 (was A$0.11). The key risk is poor clinical results for each of the programs thereby reducing the ability to partner or sell the assets. "
The key risk to the sp was poor clinical results; but the smoking cessation results were outstanding. So why the fall in the sp? What else could management have done to ensure a higher sp? Anyone have any ideas?
My previous post discussed possible reasons for the cr.
In relation to the sp - have a look at Morgan's analyst coverage...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 12.5¢ | $15.62K | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 213400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 57707 | 2 |
View Market Depth
| Last trade - 14.46pm 20/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |